logo
Plus   Neg
Share
Email

Lipocine Receives Complete Response Letter From FDA For TLANDO - Quick Facts

Lipocine Inc. (LPCN) has received a Complete Response Letter or CRL from the FDA regarding the company's New Drug Application for TLANDO, an oral testosterone product candidate. The FDA has stated that the efficacy trial did not meet the three secondary endpoints for maximal testosterone concentrations.

"We are disappointed by the FDA's decision and intend to request a meeting with the FDA as soon as possible to discuss a potential path forward for the approval of TLANDO," said Mahesh Patel, CEO of Lipocine.

Shares of Lipocine Inc. were down nearly 34% in pre-market trade on Monday.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients. Ferring Pharmaceuticals US is recalling various nasal sprays citing superpotency or amounts of desmopressin higher than specified, the U.S. Food and Drug Administration announced in a statement. The recall involves all lots on the market of DDAVP Nasal Spray 10 mcg/0.1mL, Desmopressin Acetate Nasal Spray 10 mcg/0.1mL, and STIMATE Nasal Spray 1.5 mg/mL.
Follow RTT